Steve Schonfeld’s Lexeo Therapeutics LXEO Stock Holding History

Steve Schonfeld’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-24,221	Closed	-$139K	–	2831
2026 Q1	$139K	Buy	+24,221	New	+$172K	﹤0.01%	1837

Other funds holding LXEO

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Jupiter Topco New York $245B AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Steve Schonfeld's LXEO Position: Q2 2026 in Review

Steve Schonfeld sold out of Lexeo Therapeutics (LXEO) in Q2 2026, closing a stake of 24,221 shares — an estimated $139K sold.

Steve Schonfeld first reported a position in LXEO in Q1 2026 and held it in 1 quarter. The position peaked at $139K in Q1 2026. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

Steve Schonfeld reported no remaining Lexeo Therapeutics position as of Q2 2026 after selling out during the quarter.
Steve Schonfeld sold 24,221 Lexeo Therapeutics shares in Q2 2026, an estimated $139K.
Steve Schonfeld first reported a position in Lexeo Therapeutics in Q1 2026 and held it in 1 quarter.
Steve Schonfeld's Lexeo Therapeutics position peaked at $139K in Q1 2026.
141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.